Skip to main content

Advertisement

SpringerLink
Log in

Update on Medical Management of Peyronie’s Disease

  • Men's Health (R Carrion and C Yang, Section Editors)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

The treatment of Peyronie’s disease (PD) is a challenge for the clinician. In the quest to straighten the penis, alleviate pain, prevent further shortening, and restore erectile function, many non-surgical treatments have been offered in lieu of an operative approach, which is still considered the gold standard for definitive treatment. This communication is an update on the different approaches used in the minimally invasive management of this frustrating and yet intriguing condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dunsmuir WD, Kirby R. Francois de LaPeyronie (1978–1747): the man and the disease he described. Br J Urol. 1996;78:613–22.

    Article  CAS  PubMed  Google Scholar 

  2. Nelson CJ, Diblasio C. The chronology of depression and distress in men with Peyronie disease. J Sex Med. 2008;5:1985–90.

    Article  PubMed  Google Scholar 

  3. Trost LW, Gur S. Pharmacological management of Peyronie’s disease. Drugs. 2007;67:527–45.

    Article  CAS  PubMed  Google Scholar 

  4. Muller A, Mulhall J. Peyronie’s disease intervention trials: methodological challenges and issues. J Sex Med. 2009;6:848–61.

    Article  PubMed  Google Scholar 

  5. Jarow JP, Lowe F. Penile trauma: an etiologic factor in Peyronie disease and erectile dysfunction. J Urol. 1997;158:1388–90.

    Article  CAS  PubMed  Google Scholar 

  6. El-Sakka AI, Hassoba H. An animal model of Peyronie-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol. 1997;158:2284–90.

    Article  CAS  PubMed  Google Scholar 

  7. Bivalacqua TJ, Diner E. A rat model of Peyronie disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol. 2000;163:1992–8.

    Article  CAS  PubMed  Google Scholar 

  8. Ferrini MG, Vernet D-C. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide. 2002;6:283–94.

    Article  CAS  PubMed  Google Scholar 

  9. Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie disease. Nat Clin Pract Urol. 2005;2:291–7.

    Article  CAS  PubMed  Google Scholar 

  10. Shindel AW, Bullock T. Urologist practice patterns in the management of Peyronie’s disease: a national wide survery. J Sex Med. 2008;5:954–64.

    Article  PubMed  Google Scholar 

  11. Scott WW, Scardino P. A new concept in the treatment of Peyronie’s disease. South Med J. 1948;41:173–7.

    Article  CAS  PubMed  Google Scholar 

  12. Gur S, Limin M. Current status and new developments in Peyronie’s disease: medical, minimally invasive and surgical treatment options. Expert Opin Pharmacother. 2011;12(6):931–44.

    Article  PubMed  Google Scholar 

  13. Larsen SM, Levine L. Peyronies disease: review of nonsurgical treatment options. Urol Clin N Am. 2011;38(2):195–205.

    Article  Google Scholar 

  14. Safarinejad MR, Hosseini S. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a double-blind, placebo conrolled, randomized study. J Urol. 2007;178:1398–403.

    Article  CAS  PubMed  Google Scholar 

  15. Hashimoto K, Hisasue S. Outcome analysis for conservative management of Peyronies disease. Int J Urol. 2006;13:244–7.

    Article  PubMed  Google Scholar 

  16. Paulis G, Brancato T. Efficacy of vitamin E in the conservative treatment of Peyronie’s disease: legend of reality? A controlled study of 70 cases. Andrology. 2013;1(1):120–8.

    Article  CAS  PubMed  Google Scholar 

  17. Paulis G, D’Ascenzo R. Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie’s disease: a study of 151 cases. Int J Androl. 2012;35(4):521–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Hellstrom WJ. Medical management of Peyronie’s disease. J Androl. 2009;30(4):397–405.

    Article  CAS  PubMed  Google Scholar 

  19. Zarafonetis CJ, Horrax T. Treatment of Peyronie’s disease with potassium para-aminobenzoate (potaba). J Urol. 1959;81:770–2.

    CAS  PubMed  Google Scholar 

  20. Weidner W, Hauck E. Potassium paraaminobenzoate (Potaba) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47:530–6.

    Article  CAS  PubMed  Google Scholar 

  21. Stoevesandt J, Kürzinger N. Uro-dermatological problems of a construction worker: paraaminobenzoic acid as a systemic photosensitizer. Eur J Dermatol. 2010;20(2):2217–9.

    Google Scholar 

  22. Paulis G, Brancato T. Inflammatory mechanisms and oxidate stress in Peyronie’s disease: therapeutic “rationale” and related emerging treatment strategies. Inflamm Allergy Drug Targets. 2012;11(1):48–57.

    Article  CAS  PubMed  Google Scholar 

  23. Teloken C, Rhoden E. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol. 1999;162:2003–5.

    Article  CAS  PubMed  Google Scholar 

  24. El-Sakka AI, Bakircioglu M. The effects of colchicine on a Peyronie’s-like condition in an animal model. J Urol. 1999;191:1980–3.

    Article  Google Scholar 

  25. Akkus E et al. Is colchine effective in Peyronie’s disease? A pilot study. Urology. 1994;44:291–6.

    Article  CAS  PubMed  Google Scholar 

  26. Safarinejad MR et al. Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16(3):238–43.

    Article  CAS  PubMed  Google Scholar 

  27. Prieto Castro RM, Leva Vallejo ME. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int. 2003;91(6):522–4.

    Article  CAS  PubMed  Google Scholar 

  28. Cortes-Gonzalez JR, Glina S. Conservative treatment of Peyronie’s disease: colchicine vs cochicine plus vitamin E. Actas Urol Esp. 2010;34(5):444–9.

    Article  CAS  PubMed  Google Scholar 

  29. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int. 2001;88:63–7.

    Article  CAS  PubMed  Google Scholar 

  30. Cavallini G, Biagiotti G. Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie’s disease. BJU Int. 2002;89:895.

    Article  CAS  PubMed  Google Scholar 

  31. Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie’s disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010;7(4):215–21.

    Article  CAS  PubMed  Google Scholar 

  32. Chung E, Deyoung L. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8(5):1472–7.

    Article  CAS  PubMed  Google Scholar 

  33. Shindel AW, Lin G. Pentoxifylline attenuates transforming growth factor- beta-1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracelluar matrix. J Sex Med. 2010;7(6):2077–85.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Safarinejad MR, Asgari M. A double-bind placebo-controlled study of the efficacy and safety of pentoxyfylline in early chronic Peyronie’s disease. BJU Int. 2010;106(2):240–8.

    Article  CAS  PubMed  Google Scholar 

  35. Smith JF, Shindel A. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl. 2011;13(2):322–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Safarinejad MR. Efficacy and safety of omega-3 for treatment of early-stage Peyronie’s disease. A prospective, randomized, double-blind placebo-controlled study. J Sex Med. 2009;6(6):1743–54.

    Article  CAS  PubMed  Google Scholar 

  37. Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chornic Peyronie’s disease: a double-blind, placebo-controlled study. Int J Impot Res. 2010;22(5):298–309.

    Article  CAS  PubMed  Google Scholar 

  38. Fitch 3rd WP, Easterling W. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie disease—a placebo-controlled pilot study. J Sex Med. 2007;4:477–84.

    Article  CAS  PubMed  Google Scholar 

  39. Martin DJ, Badwan K. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002;168:2483–5.

    Article  CAS  PubMed  Google Scholar 

  40. Sieg A, Wascotte V. Diagnostic and therapeutic applications of iontophoresis. J Drug Target. 2009;17:690–700.

    Article  CAS  PubMed  Google Scholar 

  41. Rothfeld SH, Murray W. The treatment of Peyronie disease by iontophoresis of C21 esterified glucocortocoids. J Urol. 1967;97:874–5.

    CAS  PubMed  Google Scholar 

  42. Di Stasi SM, Giannantoni A. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie disease. J Urol. 2004;171:1605–8.

    Article  PubMed  Google Scholar 

  43. Greenfield JM, Shah S. Verapamil versus saline in electromotive drug administration for Peyronie disease: a double- blind, placebo controlled trial. J Urol. 2007;177:972–5.

    Article  CAS  PubMed  Google Scholar 

  44. Bodner H, Howard A. Peyronie disease; cortisone- hyaluronidase-hydrocortisone therapy. Trans West Sect Am Urol Assoc. 1953;20:32–5.

    CAS  PubMed  Google Scholar 

  45. Desanctis PN, Furey C. Steroid injection therapy for Peyronie disease: a 10-year summary and review of 38 cases. J Urol. 1967;97:114–6.

    CAS  PubMed  Google Scholar 

  46. Winter CC, Khanna R. Peyronie disease: results with dermo-jet injection of dexamethasone. J Urol. 1975;114:898–900.

    CAS  PubMed  Google Scholar 

  47. Ralph D, Gonzalez-Cadavid N. The medical management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359–74.

    Article  PubMed  Google Scholar 

  48. Pryor J, Akkus E. Peyronie’s disease. J Sex Med. 2004;1:110–5.

    Article  PubMed  Google Scholar 

  49. Lue TF, Giuliano F. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004;1:6–23.

    Article  PubMed  Google Scholar 

  50. Levine LA, Merrick P. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151:1522–4.

    CAS  PubMed  Google Scholar 

  51. Levine LA, Goldman K. Experience with intra-plaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168:621–6.

    Article  CAS  PubMed  Google Scholar 

  52. Russell S, Steers W. Systematic evidence-based analysis of plaque injection therapy for Peyronie’s disease. Eur Urol. 2007;51:640–7.

    Article  PubMed  Google Scholar 

  53. Rehman J, Benet A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology. 1998;51:620–6.

    Article  CAS  PubMed  Google Scholar 

  54. Shirazi M, Haghpanah A. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo- controlled study. Int Urol Nephrol. 2009;41:467–71.

    Article  CAS  PubMed  Google Scholar 

  55. Soh J, Kawauchi A. Nicardipine vs. saline injection as treatment for Peyronie disease: a prospective, randomized, single-blind trial. J Sex Med. 2010;7:3743–9.

    Article  CAS  PubMed  Google Scholar 

  56. Duncan MR, Berman B. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25:89–94.

    Article  CAS  PubMed  Google Scholar 

  57. Ahuja S, Bivalacqua T. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie’s disease. J Androl. 1999;20:444–8.

    CAS  PubMed  Google Scholar 

  58. Brake M, Loertzer H. Treatment of Peyronie’s disease with local interferon-alpha 2b. BJU Int. 2001;87:654–7.

    Article  CAS  PubMed  Google Scholar 

  59. Hellstrom WJ, Kendirci M. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie disease. J Urol. 2006;176:394–8.

    Article  CAS  PubMed  Google Scholar 

  60. Inal T, Tokatli Z. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie disease: a randomized and prospective study. Urology. 2006;67:1038–42.

    Article  PubMed  Google Scholar 

  61. Schaeffer AJ, Burnett A. Nonsurgical interventions for Peyronie’s disease: 2011 update. J Androl. 2012;33:3–14.

    Article  CAS  PubMed  Google Scholar 

  62. Hurst LC, Badalamente M. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361:968–79.

    Article  CAS  PubMed  Google Scholar 

  63. Gelbard MK, James K. Collagenase versus placebo in the treatment of Peyronie disease: a double-blind study. J Urol. 1993;149:56–8.

    CAS  PubMed  Google Scholar 

  64. Jordan G. The use of intralesional clostridial collagenase injection therapy for Peyronie disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008;5:180–7.

    Article  PubMed  Google Scholar 

  65. Gelbard M, Lipshultz L. Phase 2b study of clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronie’s disease. J Urol. 2012;187:2268.

    Article  CAS  PubMed  Google Scholar 

  66. Gelbard M, Goldstein I. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.

    Article  CAS  PubMed  Google Scholar 

  67. Hall SJ, Basile G. Extensive corporeal fibrosis after penile irradiation. J Urol. 1995;153:372–7.

    Article  CAS  PubMed  Google Scholar 

  68. Fajardo LF, Berthrong M. Vascular lesions following radiation. Pathol Annu. 1998;23(Pt 1):297–330.

    Google Scholar 

  69. Incrocci L. Radiotherapeutic treatment of Peyronie’s disease. Expert Rev Pharmacoecon Outcomes Res. 2004;4:235–42.

    Article  PubMed  Google Scholar 

  70. Trott KR, Kamprad F. Radiobiological mechanisms of anti- inflammatory radiotherapy. Radiother Oncol. 1999;51:197–203.

    Article  CAS  PubMed  Google Scholar 

  71. Mulhall JP, Hall M. Radiation therapy in Peyronie’s disease. J Sex Med. 2012;9:1435–41.

    Article  PubMed  Google Scholar 

  72. Abdel-Salam Y, Budair Z. Treatment of Peyronie disease by extracorporeal shockwave therapy: evaluation of our preliminary results. J Endourol. 1999;13:549–52.

    Article  CAS  PubMed  Google Scholar 

  73. Hamm R, Mclarty E. Peyronie disease—the Plymouth experience of extracorporeal shockwave treatment. BJU Int. 2001;87:849–52.

    Article  CAS  PubMed  Google Scholar 

  74. Palmieri A, Imbimbo C. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie disease. Eur Urol. 2009;56:363–9.

    Article  PubMed  Google Scholar 

  75. Chitale S, Morsey M. Limited shock wave therapy vs sham treatment in men with Peyronie disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106:1352–6.

    Article  PubMed  Google Scholar 

  76. Citron N, Messina J. The use of skeletal traction in the treatment of severe primary Dupuytren’s disease. J Bone Joint Surg (Br). 1998;80:126–9.

    Article  CAS  Google Scholar 

  77. Bailey AJ, Tarlton J. The continuous elongation technique for severe Dupuytren’s disease. J Hand Surg (Br). 1994;19:522–7.

    Article  CAS  Google Scholar 

  78. Levine LA, Newell M. Penile traction therapy for treatment of Peyronie disease: a single-center pilot study. J Sex Med. 2008;5:1468–73.

    Article  PubMed  Google Scholar 

  79. Gontero P, Di Marco M. Use of penile extender device in the treatment of penile curvature as a result of Peyronie disease. Results of a phase II prospective study. J Sex Med. 2009;6:558–66.

    Article  PubMed  Google Scholar 

  80. Ferretti L, Giuliani M. Tissue engineering for penile surgery: comparative study of noncellular and cell-seeded synthetic grafts for tunica albuginea replacement. J Sex Med. 2012;9:625–31.

    Article  CAS  PubMed  Google Scholar 

  81. Imbeault A, Bernard G. Surgical option for the correction of Peyronie’s disease: an autologous tissue-engineered endothelialized graft. J Sex Med. 2011;8:3227–35.

    Article  PubMed  Google Scholar 

  82. Lin CS. Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants. Stem Cells Dev. 2012;21:2770–8.

    Article  PubMed Central  PubMed  Google Scholar 

  83. Huang YC. The effect of intracavernous injection of adipose tissue-derived stem cells on hyperlipidemia-associated erectile dysfunction in a rat model. J Sex Med. 2010;7:1391–400.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  84. Castiglione F, Hedlund P. Intratunical injection of human adipose tisse-derived stem cells prevents fibrosis and is associated with improved erectile functionin a rat model of Peyronie’s disease. Eur Urol. 2013;63:551–60.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Ronny BW Tan, Dr. Premsant Sangkum, Dr. Greg Mitchell, and Dr. Wayne JG Hellstrom each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Urology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore

    Ronny B. W. Tan

  2. Department of Urology, Tulane University School of Medicine, 1430 Tulane Ave. SL-42 Room 3520B, New Orleans, LA, 70112, USA

    Premsant Sangkum, Gregory C. Mitchell & Wayne J. G. Hellstrom

Authors
  1. Ronny B. W. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Premsant Sangkum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory C. Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wayne J. G. Hellstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wayne J. G. Hellstrom.

Additional information

This article is part of the Topical Collection on Men’s Health

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tan, R.B.W., Sangkum, P., Mitchell, G.C. et al. Update on Medical Management of Peyronie’s Disease. Curr Urol Rep 15, 415 (2014). https://doi.org/10.1007/s11934-014-0415-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-014-0415-4

Keywords

Search

Navigation